{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:37:43Z","timestamp":1777865863620,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T21:51:18Z","timestamp":1743457878000},"page":"661-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-9252","authenticated-orcid":false,"given":"Luis E.","family":"Aguirre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-1204","authenticated-orcid":false,"given":"Somedeb","family":"Ball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7238-9241","authenticated-orcid":false,"given":"Akriti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla Al","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0504-8233","authenticated-orcid":false,"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-3317","authenticated-orcid":false,"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.03.016_bib0001","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1080\/10428194.2016.1258700","article-title":"Incidence and survival outcomes of chronic myelomonocytic leukemia in the United States","volume":"58","author":"Guru Murthy","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2025.03.016_bib0002","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41375-021-01207-3","article-title":"Chronic myelomonocytic leukemia diagnosis and management","volume":"35","author":"Chan","year":"2021","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2025.03.016_bib0003","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2019-131071","article-title":"WHO-defined chronic myelomonocytic leukemia-2 (CMML-2) patients rapidly progress to AML suggesting this entity represents a transitory clinical State","volume":"134","author":"Hunter","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.016_bib0004","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc.2017.40","article-title":"Turning the tide in myelodysplastic\/myeloproliferative neoplasms","volume":"17","author":"Deininger","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"25","key":"10.1016\/j.clml.2025.03.016_bib0005","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.03.016_bib0006","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","article-title":"Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases","volume":"6","author":"Fenaux","year":"1988","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.03.016_bib0007","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","article-title":"Chronic myelomonocytic leukemia: natural history and prognostic determinants","volume":"64","author":"Tefferi","year":"1989","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.1016\/j.clml.2025.03.016_bib0008","first-page":"766","article-title":"Chronic myelomonocytic leukemia","volume":"4","author":"Storniolo","year":"1990","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.03.016_bib0009","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.03.016_bib0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08381.x","article-title":"ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia","volume":"151","author":"Gelsi-Boyer","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.03.016_bib0011","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2025.03.016_bib0012","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.03.016_bib0013","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/blood.V97.5.1427","article-title":"Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes","volume":"97","author":"Bellamy","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.03.016_bib0014","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1182\/blood.V98.4.1272","article-title":"Misleading information about ALIP and VEGF in myelodysplasia","volume":"98","author":"Mangi","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.03.016_bib0015","first-page":"3527","article-title":"Endothelial cells in physiology and in the pathophysiology of vascular disorders","volume":"91","author":"Cines","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.03.016_bib0016","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2013.100","article-title":"An evolutionary perspective on chronic myelomonocytic leukemia","volume":"27","author":"Itzykson","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2025.03.016_bib0017","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2012-06-440347","article-title":"Clonal architecture of chronic myelomonocytic leukemias","volume":"121","author":"Itzykson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.03.016_bib0018","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.clml.2025.03.016_bib0019","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.03.016_bib0020","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00277-012-1521-3","article-title":"Activating CBL mutations are associated with a distinct MDS\/MPN phenotype","volume":"91","author":"Schwaab","year":"2012","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.clml.2025.03.016_bib0021","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood.V128.22.3189.3189","article-title":"Clinical, hematological, and biologic characteristics in chronic myelomonocytic leukemia patients with a JAK2 V617F mutation","volume":"128","author":"Geissler","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.03.016_bib0022","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.3324\/haematol.2018.208082","article-title":"Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation","volume":"104","author":"Patnaik","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2025.03.016_bib0023","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.clml.2025.03.016_bib0024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.clml.2025.03.016_bib0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/bjh.15061","article-title":"Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis","volume":"183","author":"Tefferi","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.03.016_bib0026","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/PAS.0000000000001058","article-title":"Chronic myelomonocytic leukemia with fibrosis is a distinct disease subset with myeloproliferative features and frequent JAK2 p.V617F mutations","volume":"42","author":"Gur","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2025.03.016_bib0027","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.humpath.2018.10.026","article-title":"Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic leukemia from primary myelofibrosis with monocytosis","volume":"85","author":"Hu","year":"2019","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.clml.2025.03.016_bib0028","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1038\/modpathol.2012.87","article-title":"The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis","volume":"25","author":"Gianelli","year":"2012","journal-title":"Mod Pathol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:15:38Z","timestamp":1755746138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025001090"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.016","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}